JP2008504803A - 遺伝子発現の細胞型特異的パターン - Google Patents

遺伝子発現の細胞型特異的パターン Download PDF

Info

Publication number
JP2008504803A
JP2008504803A JP2006549442A JP2006549442A JP2008504803A JP 2008504803 A JP2008504803 A JP 2008504803A JP 2006549442 A JP2006549442 A JP 2006549442A JP 2006549442 A JP2006549442 A JP 2006549442A JP 2008504803 A JP2008504803 A JP 2008504803A
Authority
JP
Japan
Prior art keywords
gene
cell
level
expression
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006549442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504803A5 (enExample
Inventor
エリザベス ダフ ストュアート，
ウィリアム ワッチズマン，
ダニエル マーコーラ，
マイケル マックレランド，
ジェシカ ワン−ロドリゲス，
デイビッド タリン，
チャールズ シー． ベリー，
カレン アーデン，
リンダ ワッサーマン，
スティーブン グッディソン，
イゴアー クラカンスキー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2008504803A publication Critical patent/JP2008504803A/ja
Publication of JP2008504803A5 publication Critical patent/JP2008504803A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006549442A 2004-01-09 2005-01-07 遺伝子発現の細胞型特異的パターン Withdrawn JP2008504803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53538204P 2004-01-09 2004-01-09
US53616304P 2004-01-12 2004-01-12
PCT/US2005/000564 WO2005068664A2 (en) 2004-01-09 2005-01-07 Cell-type-specific patterns of gene expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010294923A Division JP2011229522A (ja) 2004-01-09 2010-12-15 遺伝子発現の細胞型特異的パターン

Publications (2)

Publication Number Publication Date
JP2008504803A true JP2008504803A (ja) 2008-02-21
JP2008504803A5 JP2008504803A5 (enExample) 2011-08-18

Family

ID=34798852

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006549442A Withdrawn JP2008504803A (ja) 2004-01-09 2005-01-07 遺伝子発現の細胞型特異的パターン
JP2010294923A Pending JP2011229522A (ja) 2004-01-09 2010-12-15 遺伝子発現の細胞型特異的パターン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010294923A Pending JP2011229522A (ja) 2004-01-09 2010-12-15 遺伝子発現の細胞型特異的パターン

Country Status (4)

Country Link
US (1) US8781750B2 (enExample)
JP (2) JP2008504803A (enExample)
KR (1) KR20070052694A (enExample)
WO (1) WO2005068664A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518395A (ja) * 2009-02-23 2012-08-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞株同定方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
MXPA06014116A (es) 2004-06-04 2007-08-08 Aviaradx Inc Identificacion de tumores.
DK1899484T3 (da) 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv
JP2007295822A (ja) * 2006-04-28 2007-11-15 Kusakabe Bio-Medical Research Laboratory Inc 卵巣腫瘍のシスプラチン耐性マーカー
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
KR100740582B1 (ko) * 2006-09-27 2007-07-19 한국과학기술연구원 가스크로마토그래피-질량분석기를 이용한 두 생체시료군 간대사체 차별성 분석 방법
AU2008269689A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
RU2511408C2 (ru) * 2007-09-17 2014-04-10 Конинклейке Филипс Электроникс Н.В. Способ анализа нарушений, связанных с раком яичников
CA2742531A1 (en) * 2008-11-04 2010-05-14 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 5 expression by antisense oligonucleotides
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010065940A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2011116244A2 (en) * 2010-03-17 2011-09-22 Cedars-Sinai Medical Center Methods of diagnosing and treating conditions associated with metabolic clearance rate of insulin
WO2011119531A1 (en) * 2010-03-22 2011-09-29 Esoterix Genetic Laboratories, Llc Mutations associated with cystic fibrosis
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
EP2601609B1 (en) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
AU2012209074A1 (en) * 2011-01-25 2013-07-11 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US9589099B2 (en) 2011-07-21 2017-03-07 The Chinese University Of Hong Kong Determination of gene expression levels of a cell type
EP2766483B1 (en) 2011-10-10 2022-03-23 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2773779B1 (en) 2011-11-04 2020-10-14 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
WO2013120018A1 (en) 2012-02-09 2013-08-15 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
WO2013166217A2 (en) * 2012-05-01 2013-11-07 Synapdx Corporation Systems and methods for normalizing gene expression profiles of biological samples having a mixed cell population
CA2877400A1 (en) * 2012-07-10 2014-01-16 Nepean Blue Mountains Local Health District Risk stratification in influenza
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
EP2900835B1 (en) 2012-09-27 2025-04-30 Population Bio, Inc. Method for screening and treating developmental disorders
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
EP3639841B1 (en) 2013-03-27 2023-09-06 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a
DK3019619T3 (da) 2013-07-11 2021-10-11 Modernatx Inc Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN103757028B (zh) * 2014-01-23 2015-09-09 南京医科大学 Osbpl2突变型基因、其鉴定方法和检测试剂盒
WO2015120482A2 (en) * 2014-02-10 2015-08-13 Baylor College Of Medicine Recurrent fusion genes identified in high-grade serous ovarian carcinoma
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
JP6403260B2 (ja) * 2014-11-21 2018-10-10 学校法人日本大学 前立腺癌の判定、治療選択方法、予防又は治療剤
CN104611430A (zh) * 2015-01-26 2015-05-13 钱学庆 一种人类尿液中tmprss2-erg基因检测方法和引物
WO2017095960A1 (en) * 2015-11-30 2017-06-08 Synthetic Genomics, Inc. Compositions and methods for expressing genes in algae
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
WO2018094469A1 (en) * 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
CN111727259B (zh) 2017-12-01 2024-04-19 编码治疗公司 工程化的dna结合蛋白
EP3814521A4 (en) * 2018-06-29 2022-07-27 The Jackson Laboratory SPLICING VARIANTS FOR BREAST CANCER
CA3108807A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
CN109593848B (zh) * 2018-11-08 2020-07-10 浙江大学 一种肿瘤相关序列、长链非编码rna及其应用
GB2582665B (en) * 2019-03-29 2021-12-29 Advanced Risc Mach Ltd Feature dataset classification
US12188060B2 (en) 2020-05-15 2025-01-07 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
WO2022246204A2 (en) * 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Compounds for reducing ptbp1 expression
US20250002915A1 (en) * 2021-10-25 2025-01-02 University Of Cincinnati Molecular therapeutics for the treatment of hypertrophic cardiomyopathy and heart failure associated with mybpc3 gene mutations
EP4433595A1 (en) * 2021-11-18 2024-09-25 Resonance Health Analysis Services Pty Ltd Method for treating cyclophilin b associated diseases
WO2025054611A1 (en) * 2023-09-08 2025-03-13 The Trustees Of Princeton University Systems and methods for predicting high resolution cell-type-specific gene transcription and applications thereof
CN119296651B (zh) * 2024-09-19 2025-09-19 新疆维吾尔自治区人民医院 胸主动脉夹层关键细胞类型及亚型的分类方法及装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2002062201A2 (en) * 2001-02-02 2002-08-15 Dana-Farber Cancer Institute, Inc. Rare event detection system
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002953327A0 (en) * 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
EP1627083A2 (en) * 2003-05-07 2006-02-22 Agilent Technologies, Inc. Systems and methods for determining cell type composition of mixed cell populations using gene expression signatures
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2002062201A2 (en) * 2001-02-02 2002-08-15 Dana-Farber Cancer Institute, Inc. Rare event detection system
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518395A (ja) * 2009-02-23 2012-08-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞株同定方法

Also Published As

Publication number Publication date
JP2011229522A (ja) 2011-11-17
US20060292572A1 (en) 2006-12-28
WO2005068664A3 (en) 2006-04-27
WO2005068664A2 (en) 2005-07-28
KR20070052694A (ko) 2007-05-22
US8781750B2 (en) 2014-07-15

Similar Documents

Publication Publication Date Title
JP2008504803A (ja) 遺伝子発現の細胞型特異的パターン
JP2008504803A5 (enExample)
US11644466B2 (en) Methods for treating, preventing and predicting risk of developing breast cancer
US8014957B2 (en) Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP2668296B1 (en) Colon cancer gene expression signatures and methods of use
EP2971164B1 (en) Methods and compositions for classification of samples
US8492328B2 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
AU2007340265B2 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for Raf inhibitors
US10428386B2 (en) Gene for predicting the prognosis for early-stage breast cancer, and a method for predicting the prognosis for early-stage breast cancer by using the same
US20060199204A1 (en) Genetic testing for male factor infertility
US20090258002A1 (en) Biomarkers for Tissue Status
Yamano et al. Hyaluronan-mediated motility: a target in oral squamous cell carcinoma
WO2007048074A1 (en) Method and apparatus for correlating levels of biomarker products with disease
US20190040473A1 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
CA2745961A1 (en) Materials and methods for determining diagnosis and prognosis of prostate cancer
CN101273144A (zh) 诊断食道癌的方法
KR20090078365A (ko) 혈액 백혈구 마이크로어레이 분석을 통한 전이성 흑색종의 진단 및 면역억제 지표의 모니터링
WO2003083140A2 (en) Classification and prognosis prediction of acute lymphoblasstic leukemia by gene expression profiling
EP3044333A1 (en) Methods and systems for analysis of organ transplantation
EP2794911A1 (en) Identification of multigene biomarkers
WO2004031410A2 (en) Method for diagnosing testicular seminomas
EP3298182A1 (en) Methods and compositions for diagnosing or detecting lung cancers
US20110098188A1 (en) Blood biomarkers for psychosis
US20240428948A1 (en) Unsupervised Machine Learning Methods
US20060073496A1 (en) Methods of identifying patients at risk of developing encephalitis following immunotherapy for Alzheimer's disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100928

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120203

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120906